NEW YORK (GenomeWeb) – Sygnis announced that it plans to raise up to €6.6 million ($8.1 million) through a private stock placement to help fund its planned acquisition of Australian reagent maker TGR Biosciences.

Sygnis said it will offer up to approximately 4.7 million newly issued shares to European institutional investors at a price of €1.40 per share. Proceeds from the offering will be used to acquire TGR, which Sygnis has agreed to buy for €10.4 million in cash and potentially convertible bonds.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.

Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.

The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.

In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.